Aurinia Presents New Data Underscoring Critical Importance of Earlier Lupus Nephritis Detection and Intervention and Value of LUPKYNIS® in Managing LN at American College of Rheumatology Convergence 2024
“The data we are presenting at ACR highlight the pivotal role the rheumatology community must play in diagnosing and managing lupus nephritis. Rheumatologists are on the frontlines of ensuring early detection through routine screenings and of managing LN appropriately with LUPKYNIS, which is backed by robust clinical and real-world evidence,” said Dr.
New real-world demographic data highlight high prevalence of LN among people with SLE
Using the American Rheumatology Network (ARN) electronic medical records database to understand potential renal involvement and possible signs of LN, the study included 8,631 SLE patients receiving care from community rheumatologists over a five-year time period. The analysis found that 62% of these SLE patients had ICD-10 coding or clinical laboratory measurements suggestive of LN. Of the patients with suspected LN, 97% had an eGFR assessment, compared to 66% and 62% of patients who had a protein assessment by urine test strip or urine protein, respectively. Additionally, 40% of the patients with suspected LN had an ICD-10 code specifically for LN, compared to 60% with ICD-10 codes indicating kidney conditions, eGFR decrease, or proteinuria.
“The overwhelming majority of people living with SLE show signs of potential kidney involvement. However, our analysis suggests that many SLE patients are not receiving proper kidney screenings, and that LN is under-recognized and under-coded. A more proactive approach, including regular screening for proteinuria, is crucial for earlier detection and treatment of LN to minimize irreversible kidney damage,” said Dr.
Rates of Sustained, Complete Renal Response with Long-Term Use of LUPKYNIS in LN
An analysis from the Phase 3 AURORA 1 and 2 studies highlighted the long-term efficacy of LUPKYNIS in people with LN. This study focused on a new efficacy endpoint, sustained complete renal response (SCRR), defined by the
Additional studies to be presented at ACR assessed the effectiveness of tools aimed at measuring patient-reported outcomes using data from the AURORA clinical program.
Following is the complete guide to Aurinia’s accepted abstracts at ACR 2024:
Title:
Validity, Reliability and Responsiveness of Lupus Impact Tracker and LupusPRO: AURORA Trial
Authors:
Date:
Time:
Abstract Number: 0661
Title:
Rates of Sustained Complete Renal Response with Long-term Use of Voclosporin in AURORA 2
Authors:
Date:
Time:
Abstract Number: 1545
Title:
Patient Reported Outcomes Analyses from AURORA 1 Clinical Trial: Lupus Impact Tracker and LupusPRO
Authors:
Date:
Time:
Abstract Number: 1538
Title:
Characterizing the Population with Suspected Lupus Nephritis in Care of a Community Rheumatology Network
Authors:
Date:
Time:
Abstract Number: 2415
About Lupus Nephritis
Lupus nephritis (LN) is a serious manifestation of systemic lupus erythematosus (SLE), a chronic and complex autoimmune disease. LN affects approximately 120,000 people in the
Medical guidelines recommend that all SLE patients receive routine LN screenings at every visit. Guidelines also note that delaying LN diagnosis has profound prognostic repercussions. Yet, research shows that approximately 50% of SLE patients are not screened for LN and 77% of people with LN go untreated. Aurinia is committed to improving health outcomes for people living with LN by educating patients and providers on the critical need for routine screening and transformative therapies that can help improve health outcomes.
About LUPKYNIS
LUPKYNIS is a second generation calcineurin inhibitor (CNI) with a dual mechanism of action, acting as an immunosuppressant through inhibition of T-cell activation and cytokine production and promoting podocyte stability in the kidney. The AURORA Clinical Program, comprised of the AURORA 1 pivotal trial and AURORA 2 extension trial, demonstrated the importance of LUPKYNIS plus standard of care to preserve kidney health in patients with active LN without reliance on chronic high-dose glucocorticoids. It is the only clinical program to include three years of LN treatment and follow-up with mycophenolate mofetil (MMF) and steroids.
About Aurinia
INDICATION AND IMPORTANT SAFETY INFORMATION
INDICATION
LUPKYNIS is indicated in combination with a background immunosuppressive therapy regimen for the treatment of adult patients with active lupus nephritis (LN).
Limitations of Use: Safety and efficacy of LUPKYNIS have not been established in combination with cyclophosphamide. Use of LUPKYNIS is not recommended in this situation.
IMPORTANT SAFETY INFORMATION
BOXED WARNINGS: MALIGNANCIES AND SERIOUS INFECTIONS
Increased risk for developing malignancies and serious infections with LUPKYNIS or other immunosuppressants that may lead to hospitalization or death.
CONTRAINDICATIONS: LUPKYNIS is contraindicated in patients taking strong CYP3A4 inhibitors because of the increased risk of acute and/or chronic nephrotoxicity, and in patients who have had a serious/severe hypersensitivity reaction to LUPKYNIS or its excipients.
WARNINGS AND PRECAUTIONS
Lymphoma and Other Malignancies: Immunosuppressants, including LUPKYNIS, increase the risk of developing lymphomas and other malignancies, particularly of the skin. The risk appears to be related to increasing doses and duration of immunosuppression rather than to the use of any specific agent.
Serious Infections: Immunosuppressants, including LUPKYNIS, increase the risk of developing bacterial, viral, fungal, and protozoal infections, including opportunistic infections which lead to serious, including fatal outcomes.
Nephrotoxicity: LUPKYNIS, like other calcineurin inhibitors (CNIs), may cause acute and/or chronic nephrotoxicity. The risk is increased when CNIs are concomitantly administered with drugs associated with nephrotoxicity. Monitor eGFR regularly.
Hypertension: Hypertension is a common adverse reaction of LUPKYNIS therapy and may require antihypertensive therapy. Monitor blood pressure regularly.
Neurotoxicity: LUPKYNIS, like other CNIs, may cause a spectrum of neurotoxicities: severe include posterior reversible encephalopathy syndrome (PRES), delirium, seizure, and coma; others include tremor, paresthesia, headache, and changes in mental status and/or motor and sensory functions. Monitor for neurologic symptoms.
Hyperkalemia: Hyperkalemia, which may be serious and require treatment, has been reported with CNIs, including LUPKYNIS. Concomitant use of agents associated with hyperkalemia may increase the risk for hyperkalemia. Monitor serum potassium levels periodically.
QTc Prolongation: LUPKYNIS prolongs the QTc interval in a dose-dependent manner when dosed higher than the recommended lupus nephritis therapeutic dose. The use of LUPKYNIS in combination with other drugs that are known to prolong QTc may result in clinically significant QT prolongation.
Immunizations: Avoid the use of live attenuated vaccines during treatment with LUPKYNIS. Inactivated vaccines noted to be safe for administration may not be sufficiently immunogenic during treatment with LUPKYNIS.
Pure Red Cell Aplasia: Cases of pure red cell aplasia (PRCA) have been reported in patients treated with another CNI immunosuppressant. If PRCA is diagnosed, consider discontinuation of LUPKYNIS.
Drug-Drug Interactions: Avoid co-administration of LUPKYNIS and strong CYP3A4 inhibitors or with strong or moderate CYP3A4 inducers. Co-administration of LUPKYNIS with strong CYP3A4 inhibitors is contraindicated. Reduce LUPKYNIS dosage when co-administered with moderate CYP3A4 inhibitors. Avoid use of LUPKYNIS with strong or moderate CYP3A4 inducers.
ADVERSE REACTIONS
The most common adverse reactions (≥3%) were glomerular filtration rate decreased, hypertension, diarrhea, headache, anemia, cough, urinary tract infection, abdominal pain upper, dyspepsia, alopecia, renal impairment, abdominal pain, mouth ulceration, fatigue, tremor, acute kidney injury, and decreased appetite.
SPECIFIC POPULATIONS
Pregnancy: Avoid use of LUPKYNIS.
Lactation: Consider the mother’s clinical need for LUPKYNIS and any potential adverse effects to the breastfed infant when prescribing LUPKYNIS to a lactating woman.
Renal Impairment: LUPKYNIS is not recommended in patients with baseline eGFR ≤45 mL/min/1.73 m2 unless benefit exceeds risk. If used in this population, reduce LUPKYNIS dose.
Hepatic Impairment: For mild or moderate hepatic impairment, reduce LUPKYNIS dose. Avoid use with severe hepatic impairment.
Please see Prescribing Information, including Boxed Warning, and Medication Guide for LUPKYNIS.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241115824168/en/
Media & Investor Inquiries:
achristopher@auriniapharma.com
General Investor Inquiries:
ir@auriniapharma.com
Source:
